Nantkwest (NK) Sets New 12-Month Low at $2.17

Nantkwest Inc (NASDAQ:NK) shares reached a new 52-week low on Tuesday . The stock traded as low as $2.17 and last traded at $2.20, with a volume of 137429 shares traded. The stock had previously closed at $2.25.

Several research analysts recently weighed in on the stock. Citigroup upgraded shares of Nantkwest from a “sell” rating to a “neutral” rating in a research report on Thursday, August 9th. BidaskClub upgraded shares of Nantkwest from a “sell” rating to a “hold” rating in a research report on Sunday, September 2nd. Finally, Zacks Investment Research upgraded shares of Nantkwest from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research report on Wednesday, October 10th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company’s stock. Nantkwest currently has an average rating of “Hold” and a consensus price target of $3.63.

The stock has a market cap of $179.80 million, a P/E ratio of -1.83 and a beta of 2.82. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.45 and a current ratio of 5.45.



In other Nantkwest news, Director Steve Gorlin sold 50,000 shares of the company’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $3.07, for a total transaction of $153,500.00. Following the completion of the sale, the director now owns 224,805 shares in the company, valued at approximately $690,151.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 72.30% of the company’s stock.

Several institutional investors have recently modified their holdings of NK. JPMorgan Chase & Co. increased its position in shares of Nantkwest by 40.9% in the 1st quarter. JPMorgan Chase & Co. now owns 46,068 shares of the biotechnology company’s stock valued at $179,000 after buying an additional 13,366 shares in the last quarter. A.R.T. Advisors LLC bought a new stake in shares of Nantkwest in the 1st quarter valued at $119,000. Millennium Management LLC increased its position in shares of Nantkwest by 27.9% in the 2nd quarter. Millennium Management LLC now owns 200,430 shares of the biotechnology company’s stock valued at $613,000 after buying an additional 43,686 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Nantkwest by 40.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 170,271 shares of the biotechnology company’s stock valued at $521,000 after buying an additional 49,040 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Nantkwest by 144.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 216,272 shares of the biotechnology company’s stock valued at $662,000 after buying an additional 127,694 shares in the last quarter. Institutional investors own 13.64% of the company’s stock.

Nantkwest Company Profile (NASDAQ:NK)

NantKwest, Inc engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The firm operates through the following geographical segments: United States; Europe; and Other Non-U.S.

Featured Article: What impact do institutional investors have on markets?

Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply